POCHODNE INDAZOLU JAKO ZWIĄZKI O DZIAŁANIU PRZECIWNOWOTWOROWYM

Aneta Affek; Maria Niemyjska; Martyna Wełpa

doi:10.56782/pps.70

Published : 2017-08-21

Vol. 15 No. 1 (2017)

INDAZOLE DERIVATIVES AS ANTICANCER AGENTS

Aneta Affek

Maria Niemyjska

Martyna Wełpa

DOI: https://doi.org/10.56782/pps.70

Abstract

Indazole is a heterocyclic aromatic compound. Its derivatives have a wide range of biological activities, e.g. antiinflammatory, antimicrobial and anticancer. Considering that cancer is currently one of the main causes of human mortality worldwide, the anticancer activity of indazole derivatives merits special attention. The indazole ring is a structural element of many drugs used in oncology, such as granisetron, axitinib or lonidamine. Because of this, indazole is an important lead compound in the search for novel chemotherapeutic agents with antitumor activity.

In this article the most recent literature reports that describe indazole derivatives with anticancer activity are reviewed.

Keywords:

indazole, anticancer activity, antiproliferative activity, breast cancer, lung carcinoma, hepatocellular carcinoma

Similar Articles

Nuh Korkmaz, Oğuzhan Koçer, Shahnaz Fathi, Imran Uysal, Mustafa Sevindik, Branched horsetail (Equisetum ramosissimum): some biological activities and total phenolic and flavonoid contents , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Aleksandra Mikulska, Arkadiusz Kocur, Pharmacotherapy with high doses of methotrexate (HDMTX) in oncology – how should chemotherapy be conducted based on therapeutic drug monitoring? , Prospects in Pharmaceutical Sciences: Vol. 21 No. 4 (2023)
Natalia Cichoń, Dominika Lach, Joanna Saluk-Bijak, Michał Bijak, ANTICOAGULANT THERAPY IN ACUTE CORONARY SYNDROMES AND ISCHEMIC STROKE , Prospects in Pharmaceutical Sciences: Vol. 15 No. 5 (2017)
Michał Machowski, Dorota Kaliszewska, Anna Kiss, CHROMATOGRAPHIC METHODS OF ISOLATION AND IDENTIFICATION OF FLAVONOIDS AND SAPONINS , Prospects in Pharmaceutical Sciences: Vol. 8 No. 4 (2010)
Tomasz Pieńko, CAPSAICIN – PROPERTIES, APPLICATIONS TODAY AND FUTURE PROSPECTS , Prospects in Pharmaceutical Sciences: Vol. 11 No. 2 (2013)
Aleksandra Kowalska, The Vitamin E: overview of history of discovery, mechanism of action, role and deficiency , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Dibyajyoti Saha, Satish Kumar Sarankar, Critical review on potentials of ethnopharmacological, ethnomedicinal and traditional practices of Madhuca longifolia (J. Koenig Ex L.) J. F. Macbr. (Family: Sapotaceae) , Prospects in Pharmaceutical Sciences: Vol. 21 No. 2 (2023)
Falah Saleh Mohammed, Imran Uysal, Mustafa Sevindik, Functional food Momordica charantia: biological activities , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
Celal Bal, Emre Cem Eraslan, Mustafa Sevindik, Antioxidant, antimicrobial activities, total phenolic and element contents of wild edible mushroom Bovista nigrescens , Prospects in Pharmaceutical Sciences: Vol. 21 No. 2 (2023)
Daria Żuraw, Paulina Oleksa, Mateusz Sobczyk, Kacper Jasiński, Simple obesity in children , Prospects in Pharmaceutical Sciences: Vol. 21 No. 2 (2023)

<< < 1 2 3 4 5 6 7 8 > >>

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Affek, A., Niemyjska, M., & Wełpa, M. (2017). INDAZOLE DERIVATIVES AS ANTICANCER AGENTS. Prospects in Pharmaceutical Sciences, 15(1), 1–7. https://doi.org/10.56782/pps.70

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Stańczak J., Podstawowe informacje o rozwoju demograficznym Polski do 2014 roku, www.stat.gov.pl.

Mills A. D., Nazer M. Z., Haddadin M. J., Kurth M. J., N,N-Bond-Forming Heterocyclization: Synthesis of 3-Alkoxy-2H-indazoles, J. Org. Chem, 2006, 71, 2687-2689. DOI: https://doi.org/10.1021/jo0524831

Elliott E. L., Bushell S. M., Cavero M., Tolan B., Kelly T. R., Total Synthesis of Nigellicine and Nigeglanine Hydrobromide, Org. Lett. 2005, 7 (12), 2449-2451.

Gaikwad D. D., Chapolikar A. D., Devkate C. G., Warad K. D., Tayade A. P., Pawar R. P., Domb A. J., Synthesis of indazole motifs and their medicinal importance: An overview, Eur. J. Med. Chem., 2015, 90, 701-731. DOI: https://doi.org/10.1016/j.ejmech.2014.11.029

Fischer E., Seuffert O., Ueber das Indazol, Eur. J. Inorg. Chem., 1901, 34 (1), 795-798. DOI: https://doi.org/10.1002/cber.190103401137

Minkin Y. I., Garnovskii A. D., Elguero J., Katritzky A. R., Denisko O. V., The Tautomerism of Heterocycles, Five-Membered Rings with Two ot More Heteroatoms, Adv. Heterocycl. Chem., 2000, 76, 157-323. DOI: https://doi.org/10.1016/S0065-2725(00)76005-3

Schmidt A., Beutler A., Snovydovych B., Recent Advances in the Chemistry of indazoles, Eur. J. Org. Chem., 2008, 4073-4095. DOI: https://doi.org/10.1002/ejoc.200800227

Rahman A., Malik S., Cun-heng H., Clardy J., Isolation and structure determination of nigellicyne, a novel alkaloid from the seeds of nigella sativa, Tetrahedron Lett., 1985, 26, 2759-2762. DOI: https://doi.org/10.1016/S0040-4039(00)94904-9

Liu Y.-M., Yang J.-S., Liu Q.-H., New Alkaloid and Its Artificial Derivative with an Indazole Ring from Nigella glandulifera, Chem. Pharm. Bull., 2004, 52, 454-455. DOI: https://doi.org/10.1248/cpb.52.454

Rahman A., Malik S., Hasan S. S., Choudhary M. I., Ni C.-Z., Clardy J., Nigellidine - a new indazole alkaloid from the seeds of nigella sativa, Tetrahedron Lett., 1995, 36, 1993-1996. DOI: https://doi.org/10.1016/0040-4039(95)00210-4

Abu-Irmaileh B. E., Afifi F. U., Herbal medicine in Jordan with special emphasis on commonly used herbs, J. Etnopharmacol., 2003, 89, 193-197. DOI: https://doi.org/10.1016/S0378-8741(03)00283-6

Said O., Khali K., Folder S., Azaizeh H., Ethnopharmacological survey of medicinal herbs in Israel, the Golan Heights and the West Bank region, J. Ethnopharmacol., 2002, 83, 251-265. DOI: https://doi.org/10.1016/S0378-8741(02)00253-2

Eddouks N., Maghrani M., Lemhadri A., Quahidi M. L., Jouad H., Ethnopharmacological survey of medicinal plants used for the treatment of diabetes mellitus, hypertension and cardiac diseases in the south-east region of Morocco (Tafilalet), J. Ethnopharmacol., 82, 2002, 97-103. DOI: https://doi.org/10.1016/S0378-8741(02)00164-2

Elliott E. L., Bushell S. M., Cavero M., Tolan B., Kelly T. R., Total Synthesis of Nigellicine and Nigeglanine Hydrobromide, Org. Lett. 2005, 7 (12), 2449-2451. DOI: https://doi.org/10.1021/ol050769m

Inamoto K., Katsuno M., Yoshino T., Arai Y., Hiroya K., Sakamoto T., Synthesis of 3-substituted indazoles and benzoisoxazoles via Pd-catalyzed cyclization reactions, applications to the synthesis of nigellicyne, Tetrahedron 2007, 63, 2695-2711. DOI: https://doi.org/10.1016/j.tet.2007.01.010

Thangadurai A., Minu M., Wakode S., Agrawal S., Narasimhan B., Indazole: a medicinally important heterocyclic moiety, Med. Chem. Res. 2012, 21, 1509-1523. DOI: https://doi.org/10.1007/s00044-011-9631-3

Albert D. H., Tapang P., Magoc T. J., Pease L. J., Reuter D. R., Wei R. Q., Li J., Guo J., Bousquet P. F., Ghoreishi-Haack N. S., Wang B., Bukofzer G. T., Wang Y. C., Stavropoulos J. A., Hartandi K., Niquette A. L., Soni N., Johnson E. F., McCall J. O., Bouska J. J., Luo Y., Donawho C. K., Dai Y., Marcotte P. A., Glaser K. B., Michaelides M. R., Davidsen S. K., Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor, Mol. Cancer Ther. 2006, 5, 995-1006. DOI: https://doi.org/10.1158/1535-7163.MCT-05-0410

Luo Y., Jiang F., Cole T. B., Hradil V. P., Reuter D., Chakravartty A., Albert D. F., Davidsen S. K., Cox B. F., McKeegan E. M., Fox G. B., A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model, Cancer Chemother. Pharmacol. 2012, 69, 911-921. DOI: https://doi.org/10.1007/s00280-011-1740-7

Wilhelm S. M, Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L, Lynch M., Auclair D., Taylor I. Gedrich R. Voznesensky A., Riedl B., Post L. E., Bollag G., Trail P. A., BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases ivolved in tumor progression and angiogenesis, Cancer Res. 2004, 64, 7099-7109. DOI: https://doi.org/10.1158/0008-5472.CAN-04-1443

Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R. A., Schwartz B., Simantov R., Kelley S., Discovery and development of sorafenib: a multikinase inhibitor for treating cancer, Nat. Rev. Drug Discov. 2006; 5, 835-844. DOI: https://doi.org/10.1038/nrd2130

Chu J.-H., Zhao C.-R., Song Z.-Y., Wang R.-Q., Qin Y.-Z., Wen-Bao Li W.-B., , Xian-Jun Quo X.-J., 1082-39, an analogue of sorafenib, inhibited human cancer cell growth more potently than sorafenib, Biomed. Pharmacother. 2014, 68, 335-341. DOI: https://doi.org/10.1016/j.biopha.2014.01.010

Zhao C., Wang R., Li G. Xue X., Sun C., Qu X., Li W., Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines, Bioorg. Med. Chem. Lett. 2013, 23, 1989-1992. DOI: https://doi.org/10.1016/j.bmcl.2013.02.034

Lu Y.-Y., Wang J.-J., Zhang X.-K., Li W.-B., Guo X.-L., 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases, Journal of Pharmacy and Pharmacology, 2015, 67, 1393-1405. DOI: https://doi.org/10.1111/jphp.12440

Shan Y., Dong J., Pan X., Zhang L. Zhang J., Dong Y., Wang M., Expanding the structural diversity of Bcr-Abl inhibitors, dibenzoylpiperazin incorporated with 1H-indazol-3-amine, Eur. J. Med. Chem. 2015, 104, 139-147. DOI: https://doi.org/10.1016/j.ejmech.2015.09.034

Lee J., Kim J., Hong V. S., Park J.-W., Synthesis and anti-proliferative activity evaluation of N3-acyl-N5-aryl-3,5-diaminoindazole analogues as anti-head and neck cancer agents, DARU J. Pharm. Sci. 2014, 22, 4-12. DOI: https://doi.org/10.1186/2008-2231-22-4

Song P., Chen M., Ma X., Xu L., Tao T., Yubo Zhou Y., Hu Y., Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold, Bioorg. Med. Chem. 2015, 23, 1858-1868. DOI: https://doi.org/10.1016/j.bmc.2015.02.004

Abbassi N., Geffken D., Aiello C., Gangemi R. Rosano C., Viale M., Synthesis, antiproliferative and apoptotic activities of N-(6(4)-indazolyl)-benzenesulfonamide derivatives as potential anticancer agents, Eur. J. Med. Chem. 2012, 57, 240-249. DOI: https://doi.org/10.1016/j.ejmech.2012.09.013

Abbassi N., Rakib El M., Chicha H., Bouissane L., Hannioui A., Aiello C., Gangemi R., Castagnola P., Rosano C., Viale M., Synthesis and antitumor activity of some substituted indazole derivatives, Arch. Pharm. Chem. Life Sci., 2014, 347, 423-431. DOI: https://doi.org/10.1002/ardp.201300390

Borst D. L., Arruda L. S., MacLean E., Pithavala Y. K., James E. Morgado J. E., Common questions regarding clinical use of axitinib in advanced renal cell carcinoma, Am. J. Health-Syst. Pharm. 2014, 71, 1092-1096. DOI: https://doi.org/10.2146/ajhp130581

Chen Y., Tortorici M. A., Garrett M., Hee B., Klamerus K. J., Pithavala Y. K., Clinical pharmacology of Axitinib, Clin. Pharmacokinet. 2013, 52, 713-725. DOI: https://doi.org/10.1007/s40262-013-0068-3

Pemovska T., Johnson E., Kontro M., Rapasky G. A., Chen J., Wells P., Cronin C. N., McTigue M., Kallioniemi O., Porkka K., Murray B. W., Wennerberg K., Axitinib effectively inhibits BCR-ABL1 (T316l) with a distinct binding conformation, Nature 2015, 519, 102-115. DOI: https://doi.org/10.1038/nature14119

Floridi A., Paggi M. G., Marcante M. L., Silvestrini B., Caputo A., De Martino C. J. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cell, Natl. Cancer. Inst. 1981, 66, 497-499.

Pelicano H., Martin D. S., Xu R.-H., Huang P., Glycolysis inhibition for anticancer treatment, Oncogene 2006, 25, 4633-4646. DOI: https://doi.org/10.1038/sj.onc.1209597

Di Cosimo S., Ferretti G., Papaldo P., Carlini P., Fabi A., Cognetti F., Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors, Drugs Today Barc. 2003, 39, 157-174. DOI: https://doi.org/10.1358/dot.2003.39.3.799451

De Lena M., Lorusso V., Latorre A., Fanizza G., Gargano G., Caporusso L., Guida M., Catino A., Crucitta E., Sambiasi D., Mazzei A., Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study, Eur. J. Cancer 2001, 37, 364-368. DOI: https://doi.org/10.1016/S0959-8049(00)00400-7

Laufer R., Forrest B., Li S.-W., Liu Y., Sampson P., Edwards L., Lang Y., Awrey D. E., Mao G., Plotnikova O., Leung G., Hodgson R., Beletskaya I., Mason J. M., Luo X., Xin Wei, Yao Y., Feher M., Ban F., Reza Kiarash R., Green E., Mak T. W., Pan G., Pauls H. W, The discovery of PLK4 inhibitors: (E) 3-((1H-indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents, J. Med. Chem. 2013, 56, 6069-6087. DOI: https://doi.org/10.1021/jm400380m

Sampson P. B., Liu Y., Patel N. K., Feher M., Forrest B., Li S.-W., Edwards L., Laufer R., Lang Y., Ban F., Awrey D. E., Mao G., Plotnikova O., Leung G., Hodgson R., Mason J., Wei X., Kiarash R., Green E., Qiu W., Chirgadze N. Y., Mak T. W., Pan G., Pauls H. W., The discovery of polo-like kinase 4 inhibitors, design and optimization of spiro[cyclopropane-1,3’[3H]indol]-2’(1’H)-ones as orally bioavailable antitumor agents, J. Med. Chem. 2015, 58, 130-146. DOI: https://doi.org/10.1021/jm500537u

Sampson P. B, Liu Y., Forrest B., Cumming G., Li S.-W., Patel N. K., Edwards L., Laufer R., Feher M., Ban F., Awrey D. E., Mao G., Plotnikova O., Hodgson R, Beletskaya I., Mason J. M., Luo X., Nadeem V., Wei X., Kiarash R., Madeira B., Huang P., Mak T. W., Pan G., Pauls H. W., The discovery of polo-like kinase 4 inhibitors: identification of (1R,2S)-2-(3-((E)-4-(((cis)-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5’-methoxyspiro[cyclopropane-1,3’-indolin]-2’-one (CFI-400945) as a potent orally active antitumor agent, J. Med. Chem. 2015, 58, 147-169. DOI: https://doi.org/10.1021/jm5005336

Li S.-W., Liu Y., Sampson P. B. Patel N. K., Forrest B. T., Edwards L., Laufer R., Feher M., Ban F., Awrey D. E., Hodgson R., Beletskaya I., Mao G., Mason J. M., Wei X., Luo X., Kiarash R., Green E., Mak T. W., Pan G., Pauls H. W., Design and optimization of (3-aryl-1H-indazol-6-yl)spiro [cyclopropane-1,30 -indolin]-2’ -ones as potent PLK4 inhibitors with oral antitumor efficacy, Bioorg. Med. Chem. Lett. 2016, 26, 4625-4630. DOI: https://doi.org/10.1016/j.bmcl.2016.08.063

Ye L., Ou X., Tian Y., Yu B., Luo Y., Feng B., Lin H., Zhang J., Wu S., Eur. Indazoles as potential c-met inhibitors: design, synthesis and molecular docking studies, J. Med. Chem. 2013, 65 112-118. DOI: https://doi.org/10.1016/j.ejmech.2013.04.004

Lai A., Mehmet M., Govek S., Nagasawa J., Bonnefous C., Julien J., Douglas K., Sensintaffar J., Lu N., Lee K., Aparicio A., Kaufman J., Qian J., Shao G., Prudente R., Moon M. J., Joseph J. D., Darimont B., Brigham D., Grillot K., Heyman R., Rix P. J., Hager J. H., Smith N. D., Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts, J. Med. Chem. 2015, 58, 4888-4904. DOI: https://doi.org/10.1021/acs.jmedchem.5b00054

Govek S.P, Nagasawa J. Y., Douglas K. L., Lai A. G., Kahraman M., Bonnefous C., Aparicio A. M., Darimont B. D., Grillot K. L., Joseph J. D., Kaufman J. A., Lee K.-J., Lu N., Moon M. J., Prudente R. Y., Sensintaffar J., Rix P. J., Hager J. H., Smith N. D., Optimization of an indazole series of selective estrogen receptor degraders: tumor regression in a tamoxifen-resistant breast cancer xerograft, Bioorg. Med. Chem. Lett. 2015, 25, 5163-5167 DOI: https://doi.org/10.1016/j.bmcl.2015.09.074

Aneta Affek

anetaaffek@op.pl

Affiliation:

Zakład Chemii Organicznej, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej, Warszawski Uniwersytet Medyczny, ul. Banacha 1, 02-097 Warszawa Poland

INDAZOLE DERIVATIVES AS ANTICANCER AGENTS

Aneta Affek

Maria Niemyjska

Martyna Wełpa

Abstract

Keywords:

Most read articles by the same author(s)

Similar Articles

Aneta Affek

Maria Niemyjska

Martyna Wełpa